Evaluation of Quality of Life in Patients with Metastatic Colorectal Cancer Treated with Capecitabine

PurposeThis study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective, multicenter, open-label, noncomparative study.Patients and MethodsPatients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires before cycle 1, at weeks 7 and 13, and at the end of treatment. In total, 1437 patients (mean age, 59.6 years [± 13.5 years]) were enrolled.ResultsIn women, statistically significant improvements were observed in 6 QLQ-C30 and 6 QLQ-CR38 domains (QLQ-C30: emotional function, nausea/vomiting, pain, constipation, financial problems, and body image; QLQ-CR38: future perspective, micturition problems, defecation problems, stoma-related problems, weight loss and global health status). In men, statistically significant improvements were observed in 8 QLQ-C30 and 5 QLQ-CR38 domains (QLQ-C30: emotional function, social function, pain, insomnia, appetite loss, constipation, financial problems, and future perspective; QLQ-CR38: micturition problems, defecation problems, stomarelated problems, weight loss, and global health status). Statistically significant worsening of sexual function/enjoyment occurred in both sexes.ConclusionOverall, 59%-86% of patients maintained or improved QOL during capecitabine therapy.